Sign inJoin waitlistJoin the waitlist

John Kirkwood

Co-Director, Melanoma and Skin Cancer Program at UPMC Hillman Cancer Center · UPMC Medical Education

Credentials: · · · ·

History

Melanoma and Skin Cancer Program at UPMC Hillman Cancer Center · UPMC Medical Education
Present
Prevention and Early Detection Program · UPMC Medical Education
Present
Pediatric Melanoma Program · UPMC Medical Education
Present

Medical Oncology
1976–1978
Internal Medicine
1973–1976
Yale School of Medicine
1969–1973
Oberlin College
1969

Research

Improved survival with vemurafenib in melanoma with BRAF V600E mutation
New England Journal of Medicine · 2011 · 6,152 citations
Final version of 2009 AJCC melanoma staging and classification
Journal of Clinical Oncology · 2009 · 3,581 citations
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
Review · Journal of Clinical Oncology · 2001 · 1,981 citations

AT
Ahmad Tarhini
85 papers · 3 as a fellow
Marc Ernstoff
65 papers · 6 as a fellow
Vernon Sondak
54 papers
SA
Sanjiv Agarwala
49 papers
Michael Atkins
42 papers
Diwakar Davar
40 papers · 4 as a fellow
HZ
Hassane Zarour
39 papers
Stergios Moschos
33 papers
Antoni Ribas
32 papers
Hussein Tawbi
29 papers · 3 as a fellow
Keith Flaherty
27 papers
Jeffrey Gershenwald
26 papers

Grants

NCI NCTN-Network Lead Academic Participating Site at UPMC Hillman Cancer Center
National Cancer Institute · UG1
PI · $7.7M · University of Pittsburgh at Pittsburgh
2019–2032
Melanoma and Skin Cancer Program SPORE
National Cancer Institute · P50
PI · $10.4M · University of Pittsburgh at Pittsburgh
2021–2027
Training Program in Skin Biology and Cancer
National Cancer Institute · T32
Contact PI · $973.1K · University of Pittsburgh at Pittsburgh
2014–2020
Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $185.5K · University of Pittsburgh at Pittsburgh
2019

Clinical trials

Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma
Principal investigator · Not yet recruiting · Phase 1, Phase 2
John Kirkwood
2026–2030
Sulforaphane for the Prevention of Melanoma in Patients With Multiple Atypical Nevi and a Prior History of Melanoma
Principal investigator · Recruiting · Phase 2
ECOG-ACRIN Cancer Research Group
2026–2033
Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
Principal investigator · Recruiting
John Kirkwood
2025–2031
Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi
Principal investigator · Recruiting
John Kirkwood
2025–2029